We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

By LabMedica International staff writers
Posted on 16 Nov 2026

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. More...

Even within a single tumor, cancer cells can vary in aggressiveness, while immune, connective tissue, and blood vessel cells influence the tumor microenvironment. Conventional classification based on tumor size and lymph node involvement may not fully capture this complexity. To improve understanding of these differences, researchers have developed a single-cell lung cancer atlas that uses AI to link cellular characteristics with clinical outcomes.

Researchers at LMU Munich, Charité University Hospital Berlin, and the Berlin Institute for the Foundations of Learning and Data at the Technical University of Berlin developed LuCaS+, a single-cell atlas of lung cancer. The atlas uses single-cell RNA sequencing to measure gene activity in individual cell nuclei from archived tumor tissue. Machine learning methods were then applied to identify distinct populations of cancer cells, immune cells, connective tissue cells, and blood vessel cells associated with clinical outcomes.

The study analyzed tumor samples from 454 lung cancer patients, capturing gene activity in more than 2.5 million individual cells. Researchers measured the activity of more than 2,000 genes per cell nucleus and linked these molecular profiles to clinical histories with long-term follow-up data. This approach enabled the team to assess the metastatic potential of different tumor cell populations and validate the findings in an independent patient cohort.

By combining molecular characteristics of cancer cells with those of their surrounding microenvironment, researchers developed a predictive model that significantly outperformed conventional clinical parameters. The model identified patients at higher risk of relapse than traditional assessments suggested, as well as those with more favorable prognoses. These findings highlight the potential of single-cell profiling and AI to improve lung cancer risk stratification and support more personalized treatment decisions.

Published in Nature Cancer on November 12, 2026, the LuCaS+ atlas is freely available to researchers investigating new therapeutic approaches. The resource could help identify potential treatment targets and guide future studies, although proposed therapies will require further validation in cell culture and animal models.

“For the LuCaS+ atlas, our team analyzed tumor tissue from 454 lung cancer patients. To do this, we used a method that had rarely been used before on this scale: With the help of single-cell RNA sequencing, we were able to read out the activity of over 2,000 genes per cell nucleus from archived tissue samples and thus draw on clinical histories with long follow-ups,” said Frederick Klauschen, Director of LMU’s Institute of Pathology. 

“When working with millions of cells, classical evaluation methods come up against their limits. Our machine learning methods, by contrast, recognize even the tiniest differences between individual cell types. This makes it possible to link these patterns directly to the clinical outcomes of the respective patients,” said Klaus-Robert Müller, BIFOLD director and professor at TU Berlin.

Related Links
LMU’s Institute of Pathology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.